Patents by Inventor Mark J. Mulvihill

Mark J. Mulvihill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GCN2 MODULATING COMPOUNDS AND USES THEREOF
    Publication number: 20240083897
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the activity of GCN2 and for treating related conditions, diseases, and disorders (e.g., cancer and neurodegenerative diseases).
    Type: Application
    Filed: January 21, 2022
    Publication date: March 14, 2024
    Inventors: Savithiri Ramurthy, Mark J. Mulvihill, Bradley Sherborne, Benjamin Rahemtulla, Eric P.A. Talbot, Christopher G. Thomson
  • (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS
    Publication number: 20220388964
    Abstract: The invention provides (aza)indazolyl-aryl sulfonamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as cancer, and in inhibiting GCN2 activity.
    Type: Application
    Filed: April 13, 2020
    Publication date: December 8, 2022
    Inventors: Savithri Ramurthy, Mark J. Mulvihill, Bradley Sherborne, Eric Talbot, Chris Thomson, Thomas Daniel Aicher, Fernando Padilla, Clarke B. Taylor, Peter L. Toogood
  • PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS
    Publication number: 20220356186
    Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting PERK and for treating related conditions, diseases, and disorders.
    Type: Application
    Filed: August 28, 2020
    Publication date: November 10, 2022
    Inventors: Mark J. Mulvihill, An-Hu Li, Matthew David Surman
  • PERK INHIBITING INDOLINYL COMPOUNDS
    Publication number: 20220348584
    Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting PERK and for treating related conditions, diseases, and disorders.
    Type: Application
    Filed: August 28, 2020
    Publication date: November 3, 2022
    Inventors: Mark J. Mulvihill, An-Hu Li, Matthew David Surman
  • PERK INHIBITING IMIDAZOLOPYRAZINE COMPOUNDS
    Publication number: 20220348583
    Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting PERK and for treating related conditions, diseases, and disorders.
    Type: Application
    Filed: August 28, 2020
    Publication date: November 3, 2022
    Inventors: Mark J. Mulvihill, An-Hu Li, Matthew David Surman
  • PERK INHIBITING COMPOUNDS
    Publication number: 20220332722
    Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting PERK and for treating related conditions, diseases, and disorders.
    Type: Application
    Filed: August 28, 2020
    Publication date: October 20, 2022
    Inventors: Mark J. Mulvihill, An-Hu Li, Matthew David Surman
  • SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN
    Publication number: 20190225611
    Abstract: The present invention relates to compounds according to Formula 1 and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancer, lymphocyte homing, chronic inflammation, neuropathic pain, fibrotic diseases, thrombosis, and cholestatic pruritus, mediated at least in part by ATX.
    Type: Application
    Filed: April 12, 2019
    Publication date: July 25, 2019
    Inventors: Lee BABISS, Matthew CLARK, Anthony D. KEEFE, Mark J. MULVIHILL, Haihong NI, Louis RENZETTI, Frank RUEBSAM, Ce WANG, Zhifeng XIE, Ying ZHANG
  • Substituted spirocyclic inhibitors of autotaxin
    Patent number: 10233182
    Abstract: The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancer, lymphocyte homing, chronic inflammation, neuropathic pain, fibrotic diseases, thrombosis, and cholestatic pruritus, mediated at least in part by ATX.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: March 19, 2019
    Assignee: X-Rx, Inc.
    Inventors: Lee Babiss, Matthew Clark, Anthony D. Keefe, Mark J. Mulvihill, Haihong Ni, Louis Renzetti, Frank Ruebsam, Ce Wang, Zhifeng Xie, Ying Zhang
  • SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN
    Publication number: 20180282332
    Abstract: The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancer, lymphocyte homing, chronic inflammation, neuropathic pain, fibrotic diseases, thrombosis, and cholestatic pruritus, mediated at least in part by ATX.
    Type: Application
    Filed: February 14, 2018
    Publication date: October 4, 2018
    Inventors: Lee BABISS, Matthew CLARK, Anthony D. KEEFE, Mark J. MULVIHILL, Haihong NI, Louis RENZETTI, Frank RUEBSAM, Ce WANG, Zhifeng XIE, Ying ZHANG
  • Substituted spirocyclic inhibitors of autotaxin
    Patent number: 10011601
    Abstract: The present invention relates to compounds according to Formula 1 and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancer, lymphocyte homing, chronic inflammation, neuropathic pain, fibrotic diseases, thrombosis, and cholestatic pruritus, mediated at least in part by ATX.
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: July 3, 2018
    Assignee: X-Rx, Inc.
    Inventors: Lee Babiss, Matthew Clark, Anthony D. Keefe, Mark J. Mulvihill, Haihong Ni, Louis Renzetti, Frank Ruebsam, Ce Wang, Zhifeng Xie, Ying Zhang
  • SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN
    Publication number: 20170166568
    Abstract: The present invention relates to compounds according to Formula 1 and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancer, lymphocyte homing, chronic inflammation, neuropathic pain, fibrotic diseases, thrombosis, and cholestatic pruritus, mediated at least in part by ATX.
    Type: Application
    Filed: April 3, 2015
    Publication date: June 15, 2017
    Applicant: X-Rx, Inc.
    Inventors: Lee Babiss, Matthew Clark, Anthony D. Keefe, Mark J. Mulvihill, Haihong Ni, Louis Renzetti, Frank Ruebsam, Ce Wang, Zhifeng Xie, Ying Zhang
  • SUBSTITUTED N-(2-(AMINO)-2OXOETHYL)BENZAMIDE INHIBITORS OF AUTOTAXIN AND THEIR PREPARATION AND USE IN THE TREATMENT OF LPA-DEPENDENT OR LPA-MEDIATED DISEASES
    Publication number: 20170037007
    Abstract: The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancer, lymphocyte homing, chronic inflammation, neuropathic pain, fibrotic diseases, thrombosis, and cholestatic pruritus, mediated at least in part by ATX.
    Type: Application
    Filed: April 21, 2015
    Publication date: February 9, 2017
    Inventors: Frank Ruebsam, Ce Wang, Haihong Ni, Mark J. Mulvihill, Lee Babiss, Louis Renzetti, Ying Zhang
  • Substituted pteridinones for the treatment of cancer
    Patent number: 9351974
    Abstract: Compounds of Formula I, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven or mediated at least in part by RSK. This Abstract is not limiting of the invention.
    Type: Grant
    Filed: November 12, 2012
    Date of Patent: May 31, 2016
    Assignee: OSI Pharmaceuticals, LLC
    Inventors: Meizhong Jin, Mridula Kadalbajoo, An-Hu Li, Mark J. Mulvihill, Kam W. Siu, Arno G. Steinig, Jing Wang
  • DIHYDROPTERIDINONES
    Publication number: 20140315911
    Abstract: Compounds of Formula I, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven or mediated at least in part by RSK. This Abstract is not limiting of the invention.
    Type: Application
    Filed: November 12, 2012
    Publication date: October 23, 2014
    Inventors: Meizhong Jin, Mridula Kadalbajoo, An-Hu Li, Mark J. Mulvihill, Kam W. Siu, Arno G. Steinig, Jing Wang
  • 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
    Patent number: 8735405
    Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
    Type: Grant
    Filed: April 13, 2012
    Date of Patent: May 27, 2014
    Assignee: OSI Pharmaceuticals, LLC
    Inventors: Lee D. Arnold, Cara Cesario, Heather Coate, Andrew P. Crew, Hanqing Dong, Kenneth Foreman, Ayako Honda, Radoslaw Laufer, An-Hu Li, Kristen Michelle Mulvihill, Mark J. Mulvihill, Anthony I. Nigro, Bijoy Panicker, Arno G. Steinig, Yingchuan Sun, Quinghua Weng, Douglas S. Werner, Michael J. Wyle, Tao Zhang
  • FUSED BICYCLIC KINASE INHIBITORS
    Publication number: 20140088114
    Abstract: Compounds of Formula (I), pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by at least one of MET, RON, ALK, IR, or IGF-1R. This Abstract is not limiting of the invention.
    Type: Application
    Filed: May 15, 2012
    Publication date: March 27, 2014
    Inventors: Meizhong Jin, Mark J. Mulvihill, Arno G. Steinig, Jing WANG
  • 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
    Patent number: 8653268
    Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: February 18, 2014
    Assignee: OSI Pharmaceuticals, LLC
    Inventors: Mark J. Mulvihill, Radoslaw Laufer, An-Hu Li, Arno G. Steinig
  • Substituted pyrrolo[2,3-b]-pyridines and -pyrazines
    Patent number: 8592448
    Abstract: Compounds of Formula I, as shown below and defined herein: (I) pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers mediated at least in part by Ron and/or Met.
    Type: Grant
    Filed: November 19, 2009
    Date of Patent: November 26, 2013
    Assignee: OSI Pharmaceuticals, LLC
    Inventors: Xin Chen, Melzhong Jin, Andrew Kleinberg, An-Hu Li, Mark J. Mulvihill, Arno G. Steinig, Jing Wang
  • Combination cancer therapy
    Patent number: 8575164
    Abstract: Methods and compositions for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially (a) a therapeutically effective amount of an anti-cancer agent and (b) an IGF1R inhibitor compound of Formula I, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. Suitable IGF1R inhibitor may be represented by Formula I: wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein.
    Type: Grant
    Filed: February 25, 2008
    Date of Patent: November 5, 2013
    Assignee: OSI Pharmaceuticals, LLC
    Inventors: Lee D. Arnold, Qun-Sheng Ji, Elizabeth Buck, John D. Haley, Mark J. Mulvihill
  • FUSED BICYCLIC KINASE INHIBITORS
    Publication number: 20130253197
    Abstract: Compounds of Formula I, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by at least one of RON, MET or ALK. This Abstract is not limiting of the invention.
    Type: Application
    Filed: April 30, 2013
    Publication date: September 26, 2013
    Applicant: OSI Pharmaceuticals, LLC
    Inventors: Mark J. Mulvihill, Arno G. Steinig, Andrew Philip Crew, Meizhong Jin, Andrew Kleinberg, An-Hu Li, Jing Wang